Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 17Active not recruiting 10Not yet recruiting 4Available 2Withdrawn 1Terminated 1Suspended 1Completed 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 1

Conditions

Colorectal Neoplasms 2Rectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 76Cisplatin 64Drug Therapy 63Carboplatin 63Bevacizumab 63Magnetic Resonance Spectroscopy 59Radiotherapy 57Gemcitabine 54Cyclophosphamide 54pembrolizumab 52Oxaliplatin 49Capecitabine 49toripalimab 44Paclitaxel 40tislelizumab 39Standard of Care 39fludarabine 36Injections 34Fluorouracil 34Biopsy 34venetoclax 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 28Nivolumab 28Surgical Procedures, Operative 27Irinotecan 27Docetaxel 27Leucovorin 26Dexamethasone 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × balstilimab × 1 year × Clear all
NCT07595874 2026-05-27

NEST3

City of Hope Medical Center

Phase 2 Not yet recruiting
100 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
16 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07551596 2026-05-15

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07550088 2026-04-24

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

Scripps Health

Phase 2 Not yet recruiting
17 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡